Paroxysmal Nocturnal Hemoglobinuria (PNH)
Global PNH Patient Registry
The Global PNH Patient Registry is a collaborative effort between the
Pegcetacoplan Superior to Eculizumab for Paroxysmal Nocturnal Hemoglobinuria
Original Publication Date
Article Source
External Web Content
Pegcetacoplan was superior to eculizumab in improving outcomes in patients with paroxysmal nocturnal hemoglobinuria (PNH) according to a recent study published in the New England Journal of Medicine. PNH is a rare, acquired hematologic disease that causes fatigue, increased risk…
Update for Josh: A Change in Treatment is only a Little Unsettling
2021 Treatment update
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Background: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemo
Danicopan (ACH-4471)
Danicopan (ACH-4471)
Danicopan (ACH-4471):
Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, and has potential to block the alterna
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria
While red blood cells (RBCs) and granulocytes have been more studied, platelets and reticulocytes are not commonly used in paroxysmal nocturnal hemoglobinuria
Jorge Leguizamo, MD
Institution
Georgia Cancer Specialists
Physician Status
accepting new patients
Primary Disease Area of Focus
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Leguizamo is a member of the American Society of Hematology, the Georgia Society of Clinical Oncology, the American Society of Clinical Oncology, and the International PNH interest group. He is also a Fellow of the American College of Physicians. Dr. Leguizamo speaks Spanish fluently.
How I Treat Paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa